A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs

Vaccine

Volumn 19, Issue 15-16, 2001, Pages 1879-1890

  Wachsman, M ^a   Kulka, M ^a   Smith, C C ^b   Aurelian, L ^b  

^a AuRx Inc   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Guinea pig; Herpes simplex virus type 2 mutant; HSV 2 disease; ICP10 PK

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; VIRUS DNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME SUBUNIT; GENE DELETION; HERPES; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DEFECTIVE VIRUSES; DISEASE MODELS, ANIMAL; DNA PRIMERS; GUINEA PIGS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; IMMUNIZATION; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECURRENCE; RIBONUCLEOTIDE REDUCTASES; SEQUENCE DELETION; VERO CELLS; VIRAL VACCINES;

EID: 0035961451     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00446-1     Document Type: Article

References (68)

1. Herpes simplex virus type 2 in the United States, 1976 to 1994
2. The role of immunosuppression in herpes simplex virus pathogenesis and its relationship to AIDS
3. Clinical and subclinical HSV infection resulting from exposure to asymptomatic patients
4. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region
5. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV Vaccine Study Group
6. Cutaneous ultraviolet radiation (UVR) inhibits herpes simplex virus induced lymphoproliferation in latently infected subjects
7. Lower interleukin-2 and higher serum tumor necrosis factor-a levels are associated with perimenstrual, recurrent facial Herpes simplex infection in young women
8. A pathogenic role of Th2 responses on the severity of encephalomyelitis induced in mice by herpes simplex virus type 2 infection
9. Expression of the first 811 nucleotides of the herpes simplex virus type 1 latency-associated transcript (LAT) partially restores wild-type spontaneous reactivation to a LAT-null mutant
10. The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript
11. Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency
12. A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state
13. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse
14. A herpes simplex virus type 1 latency-associated transcript mutant reactivates with normal kinetics from latent infection
15. Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes
16. Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency
17. Characterization of nerve growth factor-inducible cellular activity that enhances herpes simplex virus type 1 gene expression and replication of an ICP0 null mutant in cells of neural lineage
18. Mutations in the 5′ end of the herpes simplex virus type 2 latency-associated transcript (LAT) promoter affect LAT expression in vivo but not the rate of spontaneous reactivation of genital herpes
19. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is involved in IE gene transcription and virus growth
20. Vaccine potential of a Herpes Simplex Virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
21. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells
22. Deletion of herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vitro
23. Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation
24. Genomic sequences homologous to the protein kinase region of the bifunctional herpes simplex virus type 2 protein ICP10
25. A novel human gene homologous to the PK coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells
26. Immunity to herpes simplex virus type 2. II. Cell-mediated immunity in latently infected guinea pigs
27. Immunity to herpes simplex virus type 2: Recurrent lesions are associated with the induction of suppressor cells and soluble suppressor factors
28. Vaccinia virus recombinants expressing herpes simplex virus glycoprotein D protect guinea pigs from primary and recurrent HSV-2 cutaneous disease
29. Vaccination with recombinant herpes simplex virus glycoproteins: Protection against initial and recurrent genital herpes
30. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection
31. Construction and characterization of a replication-defective Herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease
32. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs
33. Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig
34. Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants
35. Comprehensive quantification of herpes simplex virus latency at the single-cell level
36. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation
37. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: Protection against challenge with virulent virus
38. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs
39. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses
40. Herpes simplex virus vaccines
41. Virulence and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1
42. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2
43. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs
44. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D
45. The mouse model and understanding immunity to herpes simplex virus
46. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge
47. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2
48. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease
49. DNA vaccines and immunity to herpes simplex virus
50. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2
51. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes
52. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge
53. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs
54. Protective vaccination against primary and recurrent disease caused by Herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1
55. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs
56. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
57. Binding of the GTP activating protein RAS-GAP by the PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10 PK) and activation of the RAS/MEK/MAPK mitogenic pathway are required for timely onset of HSV-2 growth
58. Herpes simplex vegetans: Atypical genital herpes infection in a patient with common variable immunodeficiency
59. Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease
60. Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia
61. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks
62. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia
63. Expression of herpes simplex virus DNA fragments located in epidermal keratinocytes and germinative cells is associated with the development of erythema multiforme lesions
64. Human Herpesviruses: A consideration of the latent state
65. AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP0)
66. Induction of cellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex virus type 1 infection, and explanation of trigeminal ganglia
67. Immunity to herpes simplex virus. Virus reactivation, modulates lymphokine (NK enhancing) activity
68. Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection